Article
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
Cell reports - 26 Sept 2013
Li Shunqiang, Shen Dong, Shao Jieya, Crowder Robert, Liu Wenbin, Prat Aleix, He Xiaping, Liu Shuying, Hoog Jeremy, Lu Charles, Ding Li, Griffith Obi L, Miller Christopher, Larson Dave, Fulton Robert S, Harrison Michelle, Mooney Tom, McMichael Joshua F, Luo Jingqin, Tao Yu, Goncalves Rodrigo, Schlosberg Christopher, Hiken Jeffrey F, Saied Laila, Sanchez Cesar, Giuntoli Therese, Bumb Caroline, Cooper Crystal, Kitchens Robert T, Lin Austin, Phommaly Chanpheng, Davies Sherri R, Zhang Jin, Kavuri Megha Shyam, McEachern Donna, Dong Yi Yu, Ma Cynthia, Pluard Timothy, Naughton Michael, Bose Ron, Suresh Rama, McDowell Reida, Michel Loren, Aft Rebecca, Gillanders William, DeSchryver Katherine, Wilson Richard K, Wang Shaomeng, Mills Gordon B, Gonzalez-Angulo Ana, Edwards John R, Maher Christopher, Perou Charles M, Mardis Elaine R, Ellis Matthew J
Abstract excerpt
To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes. Structural and copy number aberrations were found to be retained with high fidelity. However, at the single-nucleotide level, variable numbers of PDX-specific somatic events were documented, although they were only rarely...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.